Madison Vaccines, a life sciences spin-out of the University of Wisconsin, secures $8m series A.
Madison Vaccines, a biopharmaceutical spin-out from the University of Wisconsin-Madison, has closed an $8m series A ahead of planned clinical trials. The round was led by Venture Investors, and joined by venture firm Venture Management, the State of Wisconsin Investment Board, and the University of Wisconsin-Madison’s tech transfer unit the Wisconsin Alumni Research Foundation (WARF).…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
